Semaglutide
GLP-1 Receptor AgonistFDA-approvedAlso known as: Ozempic, Wegovy, Rybelsus, NN9535
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
Overview
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk for type 2 diabetes (marketed as Ozempic) and later approved at a higher dose for chronic weight management (Wegovy). It is a modified analog of human GLP-1 with 94% structural homology, engineered with key amino acid substitutions and a fatty acid side chain that dramatically extends its half-life to approximately 7 days, allowing once-weekly dosing. Semaglutide has become one of the most prescribed and culturally prominent peptide drugs in history, catalyzing the 'GLP-1 revolution' in obesity treatment. Beyond weight loss and glycemic control, emerging research suggests cardiovascular benefits, potential neuroprotective effects, and applications in addiction, liver disease (MASH/NASH), and kidney disease. An oral formulation (Rybelsus) is also available, making it one of the first oral peptide drugs.
Mechanism of Action
Semaglutide mimics the incretin hormone GLP-1, acting through multiple mechanisms: (1) Stimulates glucose-dependent insulin secretion from pancreatic beta cells, lowering blood sugar only when glucose is elevated; (2) Suppresses glucagon secretion, reducing hepatic glucose output; (3) Slows gastric emptying, prolonging satiety after meals; (4) Acts on hypothalamic GLP-1 receptors to reduce appetite and food intake centrally; (5) May improve beta-cell function and survival over time; (6) Reduces cardiovascular inflammation and atherosclerosis markers; (7) Emerging evidence for direct effects on reward circuitry in the brain, potentially reducing cravings for food and addictive substances.
Molecular Formula
C187H291N45O59
Molecular Weight
4113.58 g/mol
Sequence
Modified GLP-1 analog (His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 fatty diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly)
Dosage Protocols
Dose Range
0.25mg – 2mg
Frequency
Once weekly
Route
subcutaneous
Cycle Length
Ongoing (chronic therapy)
Start at 0.25mg for 4 weeks, escalate to 0.5mg, then optionally to 1mg or 2mg. Inject in abdomen, thigh, or upper arm. Rotate injection sites.
Source: FDA prescribing information (Ozempic)
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
2mg/mL, 3mL pen or vial
Last Updated
2026-02
Brand Ozempic/Wegovy. Brand: $1,000-1,300/mo without insurance. Compounded: $149-399/mo. Telehealth programs widely available. Most popular weight-loss peptide.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Nausea | moderate |
| Vomiting | moderate |
| Diarrhea | mild |
| Constipation | mild |
| Injection site reactions | mild |
| Pancreatitis | severe |
| Gallbladder events | severe |
| Thyroid C-cell tumors | severe |
| Muscle loss | moderate |
| Gastroparesis | moderate |
Pros & Cons
Produces the most significant weight loss of any approved pharmaceutical — average 15-17% body weight reduction
FDA-approved with extensive Phase 3 clinical trial data (STEP and SUSTAIN programs) in thousands of patients
Proven cardiovascular benefits — reduced MACE events by 20% in the SELECT trial
Once-weekly dosing provides excellent convenience and adherence
Dual benefits for weight loss and blood sugar control in diabetic patients
Significant GI side effects (nausea, vomiting) especially during dose escalation, causing ~7% discontinuation rate
Weight regain is common after discontinuation — two-thirds of lost weight may return within a year
High cost without insurance ($1,000-1,300/month) and frequent insurance coverage issues for weight loss indication
Loss of lean muscle mass alongside fat, requiring deliberate resistance training to mitigate
Supply shortages have been persistent since 2022 due to overwhelming demand
Research Studies
🩸 Blood Work
HbA1c
Baseline blood sugar levels — essential for GLP-1 therapy
Fasting Blood Glucose
Monitor for hypoglycemia risk
Lipid Panel
Baseline cholesterol and triglycerides
Kidney Function (BMP/CMP)
GLP-1s can affect renal function
Thyroid Panel (TSH, T3, T4)
GLP-1 agonists have thyroid C-cell tumor warnings in animal studies
Liver Function Panel (AST/ALT)
Baseline liver health before metabolic therapy
CBC (Complete Blood Count)
General health baseline
Most clinics require comprehensive bloodwork before prescribing GLP-1 agonists. Family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome is a contraindication.
Legal Status
FDA-approved for type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021). Prescription required. Available as oral formulation (Rybelsus). Covered by many insurance plans for diabetes; weight loss coverage varies.
💬 Community Experiences
Share Your ExperienceDown 35 lbs and counting. The appetite suppression is real — I went from constant snacking to being satisfied with normal portions. Energy levels improved dramatically around month 3.
Lost 18 lbs so far. Mild nausea the first two weeks but it subsided. Food noise is basically gone which is life-changing for someone who used to think about food constantly.
A1C dropped from 6.1 to 5.4. Fasting glucose normalized. Lost some weight too but the metabolic markers are what I was after. Occasional constipation is the main downside.
Results are there but the GI side effects were rough for me. Nausea and acid reflux during the dose titration phase. Getting better now but not the smooth ride some describe.
⚠️ Individual experiences may vary. These are user-submitted reports for informational purposes only. Always consult a healthcare professional before starting any peptide protocol.
Readers Also Viewed
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Collagen Peptides
95Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.
Related Peptides
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Collagen Peptides
Bioactive peptide fragments derived from hydrolyzed collagen protein that support skin elasticity, joint health, bone density, hair/nail growth, and gut lining integrity through stimulation of endogenous collagen synthesis.